N/A N=21 Harmony Scapulohumeral Rhythm (SHR) Reliability and Efficacy Study
Stroke, Acute
Primary: Upper Extremity Fugl-Meyer Assessment (UE FMA) — 6; 9.5; 8.2 score on scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=54 Evaluation of X-ray, Acetabular Guides and CT in THR
Total Hip Replacement
Primary: Acetabular Cup Anteversion Angle — 5.8; 3.7 degree
N/A N=511 Mi Propio Camino Intervention RCT for Blood Pressure Medication Adherence
Hypertension · Medication Adherence
Primary: Medication Adherence (Objective) — 54.9; 64.2 Percent days adherent
Phase 3 N=23 A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease
Alzheimers Disease
Primary: Change in Gene Expression Assessed by Single-cell Ribonucleic Acid Sequencing (scRNAseq) (Cells in Cerebrospinal Fluid [CSF]) — 41.25; 21.00 Differentially expressed genes
Phase 4 N=833 Staph Household Intervention for Eradication (SHINE)
Skin and Subcutaneous Tissue Bacterial Infections · Staphylococcus Aureus · MRSA - Methicillin Resistant Staphylococcus Aureus Infection
Primary: Number of Households With at Least One Skin and Soft Tissue Infection — 21; 21; 22 Households
N/A N=376 Middle Meningeal Artery Embolization for the Treatment of Subdural Hematomas With TRUFILL® n-BCA
Chronic Subdural Hematoma
Primary: Residual or Re-accumulation of the Chronic Subdural Hematoma (cSDH) (Greater Than [>] 10 Millimeter [mm]) as Assessed by an Independent Core Laboratory OR Any…
Phase 2 N=3 A Study of ELX-02 in Patients With Alport Syndrome
Alport Syndrome
Primary: Number of Participants With Adverse Events Associated With Administration of 0.75 mg/kg of ELX-02 Once Daily — 3 Participants
N/A N=613 Online Bullying Bystander Intervention for Middle Schools Phase II
Adolescent · Bullying · Technology
Primary: Student-Advocates Pre- and Post-Scale (SAPPS) — 29.29; 29.70; 34.19; 32.12 score on a scale
Phase 1 N=16 Phase I Clinical Study of AV-1959R: Abeta-targeting Anti-Alzheimer's Vaccine
Alzheimer Disease · Alzheimer Disease (AD) · Alzheimers Disease Prevention
Primary: Safety and Tolerability of AV-1959R Compared to Placebo — 5; 1; 6; 2 Participants
Phase 4 N=205 Vaginal Versus Intramuscular Progesterone for the Prevention of Recurrent Preterm Birth
Premature Birth
Primary: Preterm Birth <37 Weeks — 29; 36 Participants
N/A N=49 Feasibility and Acceptability of Using Weighted Blankets to Prevent and /or Mitigate Delirium
Delirium
Primary: Study Participants Experience Survey — 3.61 Scores on a likert scale (1-5)
Phase 4 N=81 Buspirone for the Treatment of Traumatic Brain Injury (TBI) Irritability and Aggression
Traumatic Brain Injury
Primary: Neuropsychiatric Inventory-Irritability Domain - Observer-rated Proportion Improved ≥ 3 Points Baseline to Day-91 — 30; 31 Participants
Phase 2 N=353 Study of Plozasiran (ARO-APOC3) in Adults With Mixed Dyslipidemia
Mixed Dyslipidemia
Primary: Percent Change From Baseline at Week 24 in Fasting TG — -1.7; -51.5; -57.7; -64.1 percentage change — p=<0.0001
N/A N=35 Culturally Aware AET Non-Initiation Intervention
Breast Cancer · Survivorship · Treatment Compliance
Primary: Program Feasibility — 35; 28; 29 Participants
Phase 2 N=51 Autoantibody Reduction for Acute Exacerbations of Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis, Acute Fatal Form
Primary: %Survival — 44; 7 percentage of participants